[en] The M(r) 16,000 NH(2)-terminal fragment of human prolactin (16K hPRL) is a potent antiangiogenic factor inhibiting endothelial cell function in vitro and neovascularization in vivo. The present study was undertaken to test the ability of 16K hPRL to inhibit the growth of human HCT116 colon cancer cells transplanted s.c. into Rag1(-/-) mice. For this purpose, HCT116 cells were stably transfected with an expression vector encoding a peptide that included the signal peptide and first 139 amino acid residues of human prolactin (HCT116(16K)). Stable clones of HCT116(16K) cells secreted large amounts of biologically active 16K hPRL into the culture medium. Growth of HCT116(16K) cells in vitro was not different from wild-type HCT116 (HCT116(wt)) or vector-transfected HCT116 (HCT116(vector)) cells. Addition of recombinant 16K hPRL had no effect on the proliferation of HCT116(wt) cells in vitro. Tumor growth of HCT116(16K) cells implanted into Rag1(-/-) mice was inhibited 63% in four separate experiments compared with tumors formed from HCT116(wt) or HCT116(vector) cells. Inhibition of tumor growth of HCT116(16K) cells was correlated with a decrease in microvascular density by 44%. These data demonstrate that biologically active 16K hPRL can be expressed and secreted from human colon cancer cells using a gene transfer approach and that production of 16K hPRL by these cells was capable of inhibiting tumor growth and neovascularization. These findings support the potential of 16K hPRL as a therapeutic agent for the treatment of colorectal cancer.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Bentzien, F.
Struman, Ingrid ; Université de Liège - ULiège > Département des sciences de la vie > GIGA-R : Biologie et génétique moléculaire
Martini, J. F.
Martial, Joseph ; Université de Liège - ULiège > Département des sciences de la vie > GIGA-R : Biologie et génétique moléculaire
Weiner, R.
Language :
English
Title :
Expression of the antiangiogenic factor 16K hPRL in human HCT116 colon cancer cells inhibits tumor growth in Rag1(-/-) mice
Publication date :
2001
Journal title :
Cancer Research
ISSN :
0008-5472
eISSN :
1538-7445
Publisher :
American Association for Cancer Research, United States - Maryland
Folkman J. (1990) What is the evidence that tumors are angiogenesis dependent?. J. Natl. Cancer Inst. 82:4-6.
Gross J.L., Herblin W.F., Dusak B.A., Czerniak P., Diamond M.D., Sun T., Eidsvoog K., Dexter D.L., Yayon A. (1993) Effects of modulation of basic fibroblast growth factor on tumor growth in vivo. J. Natl. Cancer Inst. 85:121-131.
Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., Ferrara N. (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (Lond.) 362:841-844.
Olson K.A., Fett J.W., French T.C., Key M.E., Vallee B.L. (1995) Angiogenin antagonists prevent tumor growth in vivo. Proc. Natl. Acad. Sci. USA 92:442-446.
Ferrara N., Clapp C., Weiner R. (1991) The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. Endocrinology 129:896-900.
Clapp C., Martial J.A., Guzman R.C., Rentier-Delure F., Weiner R.I. (1993) The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology 133:1292-1299.
Good D.J., Polverini P.J., Rastinejad F., Le Beau M.M., Lemons R.S., Frazier W.A., Bouck N.P. (1990) A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. USA 87:6624-6628.
O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., Lane W.S., Cao Y., Sage E.H., Folkman J. (1994) Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315-328.
O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., Folkman J. (1997) Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285.
Sharpe R.J., Byers H.R., Scott C.F., Bauer S.I., Maione T.E. (1990) Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4. J. Natl. Cancer Inst. 82:848-853.
Hanahan D., Folkman J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364.
Takahashi Y., Kitadai Y., Bucana C.D., Cleary K.R., Ellis L.M. (1995) Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 55:3964-3968.
Lee J.C., Chow N.H., Wang S.T., Huang S.M. (2000) Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur. J. Cancer 36:748-753.
Takahashi Y., Bucana C.D., Cleary K.R., Ellis L.M. (1998) p53, vessel count, and vascular endothelial growth factor expression in human colon cancer. Int. J. Cancer 79:34-38.
Warren R.S., Yuan H., Matli M.R., Gillett N.A., Ferrara N. (1995) Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Investig. 95:1789-1797.
Shaheen R.M., Davis D.W., Liu W., Zebrowski B.K., Wilson M.R., Bucana C.D., McConkey D.J., McMahon G., Ellis L.M. (1999) Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res. 59:5412-5416.
Tanaka T., Konno H., Matsuda I., Nakamura S., Baba S. (1995) Prevention of hepatic metastasis of human colon cancer by angiogenesis inhibitor Tnp-470. Cancer Res. 55:836-839.
Takatsuka S., Yamada N., Sawada T., Ogawa Y., Maeda K., Ohira M., Ishikawa T., Nishino H., Seki S., Hirakawa Y.S.C.K. (2000) Contribution of angiogenesis to the progression of colon cancer: Possible inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and hepatic metastasis. Int. J. Oncol. 17:253-258.
Maione T.E., Gray G.S., Hunt A.J., Sharpe R.J. (1991) Inhibition of tumor growth in mice by an analogue of platelet factor 4 that lacks affinity for heparin and retains potent angiostatic activity. Cancer Res. 51:2077-2083.
Yoon S.S., Eto H., Lin C.M., Nakamura H., Pawlik T.M., Song S.U., Tanabe K.K. (1999) Mouse endostatin inhibits the formation of lung and liver metastases. Cancer Res. 59:6251-6256.
D'Angelo G., Struman I., Martial J., Weiner R.I. (1995) Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proc. Natl. Acad. Sci. USA 92:6374-6378.
D'Angelo G., Martini J.-F., Iiri T., Fantl W.J., Martial J., Weiner R.I. (1999) 16K human prolactin inhibits vascular endothelial growth factor-induced activation of Ras in capillary endothelial cells. Mol. Endocrinol. 13:692-704.
Martini J.F., Piot C., Humeau L.M., Struman I., Martial I.A., Weiner R.I. (2000) The antiangiogenic factor 16K PRL induces programmed cell death in endothelial cells by caspase activation. Mol. Endocrinol. 14:1536-1549.
Struman I., Bentzien F., Lee H., Mainfroid V., D'Angelo G., Goffin V., Weiner R.I., Martial J.A. (1999) Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: An efficient mechanism for the regulation of angiogenesis. Proc. Natl. Acad. Sci. USA 96:1246-1251.
Duenas Z., Torner L., Corbacho A.M., Ochoa A., Gutierrez-Ospina G., Lopez-Barrera F., Barrios F.A., Berger P., Martinez de la Escalera G., Clapp C. (1999) Inhibition of rat corneal angiogenesis by 16-kDa prolactin and by endogenous prolactin-like molecules. Investig. Ophthalmol. Vis. Sci. 40:2498-2505.
Clapp C., Weiner R.I. (1992) A specific, high affinity, saturable binding site for the 16-kilodalton fragment of prolactin on capillary endothelial cells. Endocrinology 130:1380-1386.
Gospodarowicz D., Cheng J., Lirette M. (1983) Bovine brain and pituitary fibroblast growth factors: Comparison of their abilities to support the proliferation of human and bovine vascular endothelial cells. J. Cell Biol. 97:1677-1685.
Cooke N.E., Coit D., Shine J., Baxter J.D., Martial J.A. (1981) Human prolactin. cDNA structural analysis and evolutionary comparisons. J. Biol. Chem. 256:4007-4016.
Werner S., Weinberg W., Liao X., Peters K.G., Blessing M., Yuspa S.H., Weiner R.L., Williams L.T. (1993) Targeted expression of a dominant-negative FGF receptor mutant in the epidermis of transgenic mice reveals a role of FGF in keratinocyte organization and differentiation. EMBO J. 12:2635-2643.
Barkey R.J., Shani J., Goldhaber G., Barzilai D. (1981) Binding of iodinated rat and ovine prolactins to prolactin receptors and to its antibodies. Mol. Cell. Endocrinol. 23:105-113.
Greenwood F.C., Hunter W.M., Glover J.S. (1963) The preparation of 131I-labelled growth hormone of high specific radioactivity. Biochem. J. 89:114-123.
Lee H., Struman I., Clapp C., Martial J., Weiner R.I. (1998) Inhibition of urokinase activity by the antiangiogenic factor 16K prolactin: Activation of plasminogen activator inhibitor 1 expression. Endocrinology 139:3696-3703.
Taylor S., Folkman J. (1982) Protamine is an inhibitor of angiogenesis. Nature (Lond.) 297:307-312.
Mombaerts P., Iacomini J., Johnson R.S., Herrup K., Tonegawa S., Papaioannou V.E. (1992) Rag-1-deficient mice have no mature B and T lymphocytes. Cell 68:869-877.
Weidner N., Semple J.P., Welch W.R., Folkman J. (1991) Tumor angiogenesis and metastasis - Correlation in invasive breast carcinoma. N. Engl. J. Med. 324:1-8.
Gallicchio M., Hufnagl P., Wojta J., Tipping P. (1996) IFN-gamma inhibits thrombin- and endotoxin-induced plasminogen activator inhibitor type 1 in human endothelial cells. J. Immunol. 157:2610-2617.
Streit M., Riccardi L., Velasco P., Brown L.F., Hawighorst T., Bornstein P., Detmar M. (1999) Thrombospondin-2: A potent endogenous inhibitor of tumor growth and angiogenesis. Proc. Natl. Acad. Sci. USA 96:14888-14893.
Cao Y., O'Reilly M.S., Marshall B., Flynn E., Ji R.W., Folkman J. (1991) Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J. Clin. Investig. , published erratum appears in J. Clin. Investig. 102: 2031, 1998; 101:1055-1063.
Fidler I.J. (1986) Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis. Cancer Metastasis Rev. 5:29-49.